Compare CASS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | ALT |
|---|---|---|
| Founded | 1906 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.1M | 576.0M |
| IPO Year | 1996 | N/A |
| Metric | CASS | ALT |
|---|---|---|
| Price | $43.25 | $3.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $45.50 | $16.33 |
| AVG Volume (30 Days) | 101.1K | ★ 4.5M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ 37.29 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $222,318,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | $21.36 | ★ N/A |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $36.08 | $2.90 |
| 52 Week High | $47.00 | $8.75 |
| Indicator | CASS | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 31.76 |
| Support Level | $43.37 | $4.92 |
| Resistance Level | $45.25 | $5.37 |
| Average True Range (ATR) | 1.00 | 0.42 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 46.81 | 1.36 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.